Fate Therapeutics Inc. (FATE)
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago.
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient.
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024.
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.46 per share a year ago.
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.
